Dapagliflozin Tablet
Product Images NDC 70710-1380

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dapagliflozin (NDC 70710-1380). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 01)

Chemical structure of dapagliflozin, showing its molecular components including a chlorinated aromatic ring and a glucose-derived moiety linked to an ether group.*

FDA Label Image

Image (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 02)

A scatter plot graph showing the relationship between Dapagliflozin dose (mg) on a logarithmic x-axis and urinary glucose excretion (g) over 24 hours on the y-axis. Observed values and fitted lines are displayed separately for healthy subjects and subjects with type 2 diabetes mellitus (T2DM), indicating distinct data trends for each group.*

FDA Label Image

Image (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 03)

A line graph depicting HbA1c adjusted mean change from baseline over a 24-week study period. Three groups are compared: Dapagliflozin 10 mg with Metformin, Dapagliflozin 10 mg alone, and Metformin alone. The graph shows the progression of HbA1c reduction for each treatment group from week 0 to 24, with a side panel illustrating changes at week 24 (LOCF).*

FDA Label Image

Image (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 04)

A line graph depicting HbA1c percentage adjusted mean change from baseline over 24 study weeks. The chart compares placebo plus metformin and dapagliflozin 10 mg plus metformin groups, showing a greater reduction in HbA1c for the dapagliflozin group. Error bars indicate variability at week 24 (LOCF).*

FDA Label Image

Figure 4 (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 05)

A line graph comparing the percentage of patients with events over 60 months from randomization between dapagliflozin and placebo groups. The x-axis represents months from randomization, while the y-axis shows the percentage of patients with events. Two lines are displayed: a solid line for dapagliflozin and a dotted line for placebo, with placebo showing a higher event rate. The number of patients at risk at various time points is listed below the graph for each group.*

FDA Label Image

Figure 5 (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 06)

A line graph comparing the percentage of patients with an event over 60 months from randomization between Dapagliflozin and placebo groups. The y-axis shows the percentage of patients with events, and the x-axis shows time in months. Dapagliflozin shows a consistently lower event rate than placebo. Patient risk numbers are listed below the chart for both groups at multiple time points.*

FDA Label Image

Image (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 07)

Label for Dapagliflozin Tablets 5 mg oral tablets, manufactured by Zydus Lifesciences Ltd. and distributed by Zydus Pharmaceuticals (USA) Inc. The package contains 30 film-coated tablets. The label includes storage instructions, dispensing guidelines, and child-resistant packaging information. The NDC is 70710-1380-3.*

FDA Label Image

Image (9ca0450e 2bb5 4680 B8c8 F29148d1ddf7 08)

Label for Dapagliflozin Tablets 10 mg oral tablets by Zydus Pharmaceuticals USA Inc. The label shows the NDC number 70710-1381-3, package size of 30 tablets, and dispensing instructions for pharmacists. It includes storage guidance, child safety warnings, and manufacturer details from Zydus Lifesciences Ltd., India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.